Article

Overcoming challenges to successful recruitment of individuals at the earliest stages of disease: An example from Parkinson’s disease research

2025-06-18

Abstract excerpt

<h4>Background/Aims</h4> The Parkinson Progression Markers Initiative (PPMI) is an international, longitudinal, observational study that acquires comprehensive clinical, imaging and genetic data, as well as cerebral spinal fluid (CSF) and blood biological samples from individuals in all stages of Parkinson’s disease (PD) to develop biomarkers that accelerate therapeutic development. The effort to enroll a large po...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8e28508d-3ad7-5d27-98a1-16e53b7b1609
DOI: 10.1101/2025.06.17.25329789

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Overcoming challenges to successful recruitment of individuals at the earliest stages of disease: An example from Parkinson’s disease researchDOI 10.1101/2025.06.17.25329789Read

Safety and Feasibility of Serial Lumbar Punctures: Long-term Results from the Parkinson’s Progression Markers InitiativeSemantic proximity Read

Insights from a nationwide study of 10,929 Australians living with Parkinson’s disease: Risk factors, comorbidities, and sex differencesSemantic proximity Read

Molecular Integration in Neurological Diagnosis (MIND) Parkinson's Disease Inception Cohort Study ProtocolSemantic proximity Read

Fox Insight Collects Online, Longitudinal Patient-Reported Outcomes and Genetic Data on Parkinson’s diseaseSemantic proximity Read

AccessPD - a ‘next generation’ registry to accelerate Parkinson’s disease researchSemantic proximity Read

Disease progression strikingly differs in research and real-world Parkinson's populationsSemantic proximity Read

Fox Insight collects online, longitudinal patient-reported outcomes and genetic data on Parkinson's disease.Semantic proximity Read

Disease‑Modifying Trials in Parkinson’s Disease: Challenges, Lessons, and Future DirectionsSemantic proximity Read

Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional studySemantic proximity Read

Fox Insight at 5 years - a cohort of 54,000 participants contributing longitudinal patient-reported outcome, genetic, and microbiome data relating to Parkinson's disease.Semantic proximity Read

Novel Variants Linked to the Prodromal Stage of Parkinson’s Disease (PD) PatientsSemantic proximity Read

Predicting Cerebrospinal Fluid Alpha-Synuclein Seed Amplification Assay Status from Demographics and Clinical DataSemantic proximity Read